Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.41 |
| ▸ | CSNK1G2 | P78368 | 3/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2893250 | 0.88 | MEN1 (0.60) | MEN1KMT2APIM1MAPTKDM4E | |
| SCHEMBL1663100 | 0.85 | MEN1 (0.68) | MEN1KMT2APIM1MAPTKDM4E | |
| SCHEMBL1333872 | 0.79 | MEN1 (0.51) | MEN1KMT2APIM1MAPTKDM4E | |
| SCHEMBL14881698 | 0.78 | MEN1 (0.71) | MEN1KMT2APIM1MAPTALDH1A1 | |
| SCHEMBL2891699 | 0.77 | RIPK1 (0.62) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL20685321 | 0.76 | MTOR (0.46) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL20685494 | 0.76 | MEN1 (0.46) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL20685416 | 0.75 | MEN1 (1.00) | MEN1KMT2APIM1MAPTKDM4E | |
| SCHEMBL13058909 | 0.74 | KMT2A (0.53) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL2361973 | 0.74 | POLB (0.46) | MEN1KMT2AMAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614330-B2 | Substituted benz-azoles and methods of their use as inhibitors of RAF kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20120288501-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. FORMERLY KNOWN AS CHIRON CORPORATION (US) | 2012-11-15 | — | — | US | disclosed |
| US-8299108-B2 | for treatment of hematological/hormone-dependent cancer | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-20100196368-A1 | SUBSTITUTED BENZ-AZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-7728010-B2 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| EP-1499311-B1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-20070299039-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | CHIRON CORPORATION (US) | 2007-12-27 | — | — | US | disclosed |
| EP-1675584-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE | CHIRON CORPORATION (US) | 2006-07-05 | — | — | EP | disclosed |
| US-7071216-B2 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | CHIRON CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| WO-2005032548-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE | CHIRON CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
| EP-1499311-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS | Chiron Corporation (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-06-24 | — | — | US | disclosed |
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-05-06 | — | — | US | disclosed |
| WO-2003082272-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | MEN1 1815/4885KMT2A 1400/4885PIM1 261/4885 |
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | MEN1 1472/4885KMT2A 1162/4885PIM1 227/4885 |
| US-20120288501-A1 | SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | BRAF, RAF1, ARAF | MEN1 1815/4885KMT2A 1400/4885PIM1 261/4885 |
| US-20100196368-A1 | SUBSTITUTED BENZ-AZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE | BRAF, RAF1, ARAF | MEN1 1472/4885KMT2A 1162/4885PIM1 227/4885 |
| US-20070299039-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | MEN1 1472/4885KMT2A 1162/4885PIM1 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.